Cargando…

Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis

BACKGROUND: Mechanisms of resistance have been described during disease progression (PD) for patients under treatment with anti-EGFR plus chemotherapy (CT). The aim of our study was to evaluate efficacy of anti-EGFR rechallenge (ReCH) and reintroduction (ReIn) in metastatic colorectal cancer (mCRC)....

Descripción completa

Detalles Bibliográficos
Autores principales:	Karani, Amanda, Felismino, Tiago Cordeiro, Diniz, Lara, Macedo, Mariana Petaccia, Silva, Virgilio Souza e, Mello, Celso Abdon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2020
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373642/ https://www.ncbi.nlm.nih.gov/pubmed/32728385 http://dx.doi.org/10.3332/ecancer.2020.1069

Ejemplares similares

Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022)

The prognostic influence of tumour budding in Western patients with stage II colorectal cancer
por: Canguçu, Augusto Leite, et al.
Publicado: (2020)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2023)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions
por: de Macedo, Mariana Petaccia, et al.
Publicado: (2015)

Reintroduction
por: Bindenagel Šehović, Annamarie
Publicado: (2017)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
por: Nishimura, Nobutaka, et al.
Publicado: (2022)

Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis
por: Felismino, Tiago Cordeiro, et al.
Publicado: (2020)

Evaluation of prognostic factors in patients undergoing first-line chemotherapy for advanced biliary tract cancer: a retrospective analysis from a South American cancer centre
por: Felismino, Tiago Cordeiro, et al.
Publicado: (2022)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2018)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941
por: Ciardiello, Davide, et al.
Publicado: (2022)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma
por: Kasahara, Ryo, et al.
Publicado: (2017)

Chemotherapy rechallenge in metastatic colon cancer: A case report and literature review
por: Reddy, Tejaswini Parlapalle, et al.
Publicado: (2020)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020)

Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
por: Masuishi, Toshiki, et al.
Publicado: (2020)

To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
por: Sevindik, Omur Gokmen, et al.
Publicado: (2022)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Gut microbiota in reintroduction of giant panda
por: Tang, Jingsi, et al.
Publicado: (2020)

Ethical Considerations for Wildlife Reintroductions and Rewilding
por: Thulin, Carl-Gustaf, et al.
Publicado: (2020)

Tackling the Threat of Rabies Reintroduction in Europe
por: Vega, Santiago, et al.
Publicado: (2021)

The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report
por: Ning, Wei, et al.
Publicado: (2023)

Consistent Response on Challenge and Rechallenge of Liposomal Irinotecan in a Patient with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine plus Nab-Paclitaxel: A Case Report
por: Kim, Seong-Ryong, et al.
Publicado: (2021)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)

Lobaplatin hyperthermic intraperitoneal chemotherapy plus cytoreduction and rechallenge using cetuximab for wild-type RAS peritoneal metastatic colon cancer: a case report and literature review
por: Dai, Peilin, et al.
Publicado: (2022)

Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer
por: Ma, Jian, et al.
Publicado: (2017)

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study
por: Byeon, Seonggyu, et al.
Publicado: (2020)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
por: Mariani, Stefano, et al.
Publicado: (2022)

How to plan reintroductions of long-lived birds
por: Morandini, Virginia, et al.
Publicado: (2017)

Rechallenge of lamotrigine after development of rash
por: Houser, Jennifer, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8nti66g4qqujcqib6n0ho9kssu